Aptamer Group appoints Tim Sykes as a Non-Executive Director

Aptamer Group

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced the appointment of Tim Sykes to its Board of Directors as a Non-Executive Director with immediate effect.

Tim is an experienced executive and non-executive director, having been CEO and, previously, CFO of Proactis Holdings PLC between 2006 and 2022 and having served as fractional or transitionary CFO at Avacta Group plc, Altitude Group, and Eleco plc.  Tim currently serves as Non-Executive Director at Data Connect Group Limited and as fractional CFO at Rio AI Limited.  Tim is a qualified chartered accountant, and at Aptamer Group he is Chair of the Audit Committee and a member of the Remuneration Committee.

Dr Adam Hargreaves, Chair of the Board of Aptamer Group, commented: “As we refocus the Group to capitalise on the Optimer assets that have been developed, it is important that the Aptamer Board has the right commercial, financial and operational expertise to support this. We are excited to welcome Tim to the Board, confident that his insights will be invaluable in shaping our capital market strategy and enhancing the financial management of the business.”

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, added: “With our platform technologies gaining traction and strong performance validation across the life sciences and healthcare sectors, we are evolving our Board to align with the strategic needs of the company. Tim’s extensive experience in managing AIM-listed companies will be a crucial asset as we continue to grow.”

Tim Sykes, Non-Executive Director of Aptamer Group, said: “I’m delighted to be joining the Board of Aptamer Group at this critical time for the Company, where the focus on strategic Optimer assets represents a potential significant value inflection point. I look forward to collaborating with the Board and management team at Aptamer, leveraging my experience to contribute to the Company’s strategic direction and future success.”

Additional disclosures regarding Mr Sykes’ appointment

The following details in relation to the appointment of Timothy James Sykes, aged 54, are disclosed in accordance with Schedule 2(g) of the AIM Rules:

Current directorships:Former appointments within the past 5 years:
Data Connect Group LimitedMooring Management (Filey) LimitedProactis Holdings PLC

In 2018, Mr Sykes was a director of Penta Financial Direction Limited when it was liquidated with no loss to creditors.

In 2017, Mr Sykes was a director of Proactis Total Procure Limited, which was a Proactis joint venture in India, when it was compulsorily struck off having ceased to trade.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Aptamer Group secures £192k contracts with global pharma, boosting FY26 order book to £1.95m

Aptamer Group announced two new contracts worth £192,000, including a fourth engagement with a top five global pharmaceutical company and a new deal targeting acute myeloid leukaemia.

Aptamer Group reports strong FY2025 growth and expands Optimer® portfolio

Aptamer Group delivered strong progress in FY2025, achieving a 40% revenue increase and expanding its portfolio of licensable Optimer® assets from four to eleven.

Aptamer Group delivers 40% revenue growth and expands licensing portfolio

Aptamer Group has announced its full-year results for the twelve months ended 30 June 2025, delivering a 40% increase in revenue to £1.2 million and expanding its Optimer® licensing portfolio from four to eleven assets.

Aptamer Group secures repeat contract for Optimer® binder development

Aptamer Group has signed a new agreement with an existing partner to develop Optimer® binders targeting two proteins for biomarker research.

Aptamer Group to announce full year 2025 results on 14 October

Aptamer Group will publish results for the year ended 30 June 2025 on Tuesday, 14 October 2025, with an online analyst briefing at 9.30 am hosted by CEO Dr Arron Tolley and CFO Andrew Rapson. .

Aptamer Group secures £360,000 contract with top 3 global pharma

Aptamer Group has signed a £360,000 development contract with a leading global pharmaceutical company to engineer Optimer® binders as targeted radiopharmaceuticals.

    Search

    Search